.png)
Corporate Strategy Updates -BioNTech, Pfizer, and Astra Zeneca+BMS
We've been keeping EyesOn Strategic moves in the BioPharma space. Today we look at BioNTech's new CEO, Pfizer's continuing restructuring moves to remain competitive, and the reactions to a potential BMS + AZN merger.
BioNTech - Guido Oelkers, Ph.D., the CEO of Sobi, has moved across to take the top position at mRNA pioneer BioNTech, filling one of the most keenly followed positions in biopharma.
After CEO Ugur Sahin, M.D., and his co-founder, chief medical officer, and wife Özlem Türeci, M.D., announced in March that they would be starting a new firm focusing on next-generation mRNA breakthroughs, there has been a six-month delay in finding out who will lead the German company.
Following its establishment in 2008, BioNTech became well-known and profitable as a result of its collaboration with Pfizer on the popular COVID-19 vaccine Comirnaty. More recently, BioNTech has been preparing to press for the approval of trastuzumab pamirtecan, a HER2-targeted antibody-drug combination licensed from China’s DualityBio, as part of its aim to become a fully integrated immunotherapy powerhouse.
Trastuzumab pamirtecan and an OncoC4-partnered gotistobart are just two examples of the phase 3 oncology readouts that BioNTech has already hailed as a catalyst-rich year in 2026. Recently, the Mainz, Germany-based business reported promising anti-tumor activity from its PD-L1xVEGF-A bispecific immunomodulator pumitamig, which is collaborating with Bristol Myers Squibb.
Since taking over as CEO of the Swedish pharmaceutical company Sobi in 2017, Oelkers has managed the licensing of AstraZeneca’s respiratory syncytial virus therapy Synagis, the $915 million purchase of Dova Pharmaceuticals for the thrombocytopenia medication Doptelet, and the introduction of another bleeding disorder medication, Altuviiio, in collaboration with Sanofi.
BioNTech commended Oelkers in this week’s announcement for his proven ability to change and scale multinational corporations, fostering sustainable growth via focused capital allocation, disciplined execution, and operational excellence.
Sahin, the departing CEO of BioNTech, stated that he has come to know Guido Oelkers as a leader who combines a thorough understanding of the pharmaceutical industry with strong strategic acumen and genuine respect for the organization’s culture and people. With Guido Oelkers taking over, he feels confident that BioNTech is in a strong position to realise its vision.
Oelkers, who will assume his new role by February 1, 2027 at the latest, stated that BioNTech’s robust late-stage cancer pipeline and scientific background set it apart.
Oelkers said it is a great honour to lead BioNTech and prioritise its development into a multinational biopharmaceutical company with many approved drugs by 2030, all the while advancing its cutting-edge pre-clinical and clinical portfolio in accordance with the firm’s plan.
According to BioNTech, the appointment was the outcome of a thorough screening procedure overseen by the supervisory board. Türeci’s replacement as CMO is still being sought after.
For More Details:
Pfizer - Starting next year and continuing into 2029, Pfizer will make another wave of cost reductions of $2.5 billion. The proposal was revealed by the New York corporation in its earnings report for the second quarter.
The savings initiative coincides with a quarter in which Pfizer exceeded forecasts by increasing revenue by 3% to $15 billion. At the halfway mark, the company increased its sales forecast for 2026 by $500 million to a range of $60.5 billion to $62.5 billion.
Pfizer’s overall cost-savings goal is now $9.7 billion until 2029 thanks to the additional cuts. Pfizer’s cost realignment program will get the remaining $1 billion from the new $2.5 billion endeavor, of which $1.5 billion will be used to optimize the company’s manufacturing operations.
By the end of 2029, the corporation is expected to save $6.7 billion thanks to the cost realignment plan. This year, Pfizer is investing $500 million of the cost savings in research and development.
According to Pfizer, the manufacturing optimisation effort is concentrated on improving the product portfolio, altering the network structure, and increasing operational efficiencies.
Overall, Pfizer stated that the cost savings will create future development prospects and enhance margin expansion through productivity increases.
In addition to non-cash expenditures for accelerated depreciation and asset write-downs, Pfizer will incur a one-time expenditure of $6 billion to install and implement the new cost savings. The majority of this amount will go into severance, implementation, and existing costs.
The initiative is an extension of Pfizer’s reorganisation, which began in 2023 after the company acquired antibody-drug conjugate expert Seagen for $43 billion. At the end of that year, the buyout increased Pfizer’s workforce to 88,000, but it has since declined, going down to 75,000 by the end of 2025.
Given Pfizer’s 10% sales spike in the second quarter of 2025, which was ascribed to contractual agreements for the COVID drugs Comirnaty and Paxlovid, analysts had anticipated a year-over-year fall in the company’s quarterly revenue.
Pfizer’s growth products, such as the blood thinner Eliquis, which saw a 21% increase, and the migraine medication Nurtec, which saw an 18% increase, prospered while the COVID products saw significant declines, such as Paxlovid sales, which fell from $427 million in the second quarter of last year to $21 million in the same period this year.
Orgovyx (+51%), Lorbrena (+41%), and Padcev (+23%) were among Pfizer’s cancer drugs that increased, contributing to a 9% increase in the oncology portfolio.
Pfizer’s Vyndaqel medication family had a 9% increase despite fresh competition from Alnylam and BridgeBio in ATTR-CM.
The return of RSV shot Abrysvo, which was up 46%, was another encouraging development.
Pfizer’s updated revenue forecast, according to interim chief financial officer Cecile Guegan, shows good non-COVID product performance. The rise includes a $1 billion drop in the company’s projected sales of COVID goods from $5 billion to $4 billion, as well as a $1.5 billion gain in expected sales from non-COVID products.
The low infection level, which primarily affects Paxlovid, is reflected in the company’s performance thus far. However, the business continues to make money for Comirnaty in the latter half of this year, in line with the immunisation season.
For More Details:
Astra Zeneca + BMS - were rumored to be contemplating a merger worth $400 billion. A megadeal that would be among the biggest in history.
The corporations have been talking about a merger for the past few months, but it is uncertain if the deal will go through. It would be one of the biggest mergers ever.
In order to take advantage of higher values in the US market while maintaining its London listing, AstraZeneca announced intentions for a direct U.S. listing last year.
During Pascal Soriot’s 14 years as CEO, the company’s share price has more than doubled, surpassing both the primary British rival GSK and the broader FTSE 100 index.
According to AstraZeneca’s second-quarter results, which were released last week, growth is still being driven by the high demand for medications for rare diseases and cancer. Nearly half of all sales in 2025 came from cancer treatments, which brought in approximately $25 billion. Cardiovascular, renal, and metabolic medicines came in second with around $12 billion.
Joining up with BMS would initially strengthen AZ’s presence in the United States. Bringing over AZ’s portfolio, which the British business projects would rise from $55.6 billion in revenue in 2025 to $80 billion in 2030, could easily give growth impetus to BMS.
Some analysts are taking the opposite view saying that in actuality, combining AZ and BMS could be disastrous. They claim that merging the two pharmaceutical companies will harm patients and the larger biopharma ecosystem, cause major pipeline interruptions, raise serious regulatory issues, and cost many jobs.
Furthermore, AZ has no U.S. void. The United States accounted for 43% of AZ’s total product revenue last year. The business plans to invest $50 billion in the United States by 2030, with certain expansions already underway. Like its European rival Novartis, AZ can easily expand its U.S. footprint naturally rather than sealing a megadeal to do so.
BMS is primarily focused on the United States. Merging the two would only result in an operationally overlapping large corporation in the same market rather than opening up any new growth regions. The startling portfolio similarities between AZ and BMS could arguably foster conditions of distrust and rivalry.
The issue of repetition transcends geographical boundaries. Checkpoint inhibitors are one of the most obvious obstacles. The only two commercial anti-CTLA-4 medicines, Yervoy and Imjudo, are marketed by BMS and AZ. Additionally, the two companies’s anti-PD-(L)1 antibodies, Opdivo and Imfinzi, target some of the same indications.
AZ has advanced their BCMAxCD19 dual-targeting CAR-T treatment, AZD0120, into phase 3 trials in first-line and previously treated multiple myeloma, possibly endangering BMS’s BCMA-directed Abecma.
In the meantime, AZ’s TROP2 ADC Datroway may face direct competition from BMS’s EGFRxHER3 antibody-drug combination, izalontamab brengitecan, in the treatment of lung and breast cancer.
Anti-trust issues are raised by the two firms’s similar therapeutic aims as well as their size. Aggressive R&D reorganisation and program reprioritisation are anticipated in order to appease regulators and eliminate repetitive labour. There would be fewer treatments available to patients if promising compounds were shelved just to meet corporate goals.
Analysts also claim that while a megadeal with AstraZeneca might increase BMS’s earnings, it would also increase operational responsibilities and jeopardise the very R&D engine needed to safeguard the company’s future.
For More Details:
